Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 41.99% | -2,134.17% | -512.44% | -540.11% | -607.67% |
| Total Depreciation and Amortization | 100.00% | -- | -190.05% | -193.19% | -196.40% |
| Total Amortization of Deferred Charges | -65.79% | -59.12% | -0.75% | -23.24% | -35.32% |
| Total Other Non-Cash Items | 26.09% | 16.70% | -44.39% | 133.86% | 63.30% |
| Change in Net Operating Assets | 13.15% | -187.55% | -139.28% | -167.92% | -161.75% |
| Cash from Operations | 64.75% | -146.23% | -133.84% | -150.71% | -159.62% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -49.82% | -49.82% | -- | -- | -- |
| Issuance of Common Stock | 2,895.12% | 2,408.41% | 72.40% | -39.67% | -28.87% |
| Repurchase of Common Stock | -5.01% | 42.41% | 45.72% | -495.00% | -729.87% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -11.95% | 100.00% | 100.00% | 100.00% |
| Cash from Financing | 292.02% | 266.19% | -340.07% | -350.49% | -328.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 161.40% | -24.03% | -165.80% | -186.66% | -186.93% |